ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
CERo Therapeutics Holdings Inc

CERo Therapeutics Holdings Inc (CERO)

0,285
0,0362
( 14,55% )
Mis à jour : 18:08:20

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

Dernier
0,285
Prix Achat
0,2826
Prix Vente
0,2838
Volume échangé
9 243 487
0,239 Fourchette du Jour 0,285
0,0636 Plage de 52 semaines 12,38
Clôture Veille
0,2488
Ouverture
0,2402
Dernière Transaction
1
@
0.285
Dernière heure de transaction
18:08:19
Volume moyen (3 m)
68 632 299
Volume financier
US$ 2 484 681
VWAP
0,268803

CERO Dernières nouvelles

CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia

SOUTH SAN FRANCISCO, Calif, Nov. 15, 2024 (GLOBE NEWSWIRE) --  CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next...

CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity

Data presented as part of a poster at the SITC 2024 Conference SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) --  CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an...

CERo Therapeutics, Inc. Provides Corporate Update

Company announces submission of IND Clinical Hold Complete Response Letter SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO...

CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer

SOUTH SAN FRANCISCO, Calif, Oct. 02, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation...

CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236

Company requests Type A Meeting with U.S. Food and Drug Administration regarding clinical hold for CER-1236; announces key management changes SOUTH SAN FRANCISCO, Calif., Sept. 25, 2024 (GLOBE...

CERo Therapeutics, Inc. Presents CER-1236 Data Supporting Use in AML at Global Cell & Gene Therapy Summit 2024

Company anticipates initial human trials to focus on AML upon IND clearance SOUTH SAN FRANCISCO, Calif., July 08, 2024 (GLOBE NEWSWIRE) --  CERo Therapeutics Holdings, Inc. (Nasdaq: CERO...

CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236

Company anticipates near term filing of Investigational New Drug Application to FDA SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq:...

CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236

Company continuing IND-enabling activities in preparation for submission of Investigational New Drug Application to FDA SOUTH SAN FRANCISCO, Calif., June 06, 2024 (GLOBE NEWSWIRE) --  CERo...

CERo Therapeutics, Inc. Provides Corporate Update for Shareholders

SOUTH SAN FRANCISCO, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq:CERO) (“CERo”) an innovative immunotherapy company seeking to advance the next generation...

CERo Therapeutics, Inc. Presents Encouraging Preclinical Data for AML on CER-1236 at Stanford Drug Discovery Symposium Highlighting Tumor Elimination and Manufacturing Attributes

SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) (“CERo”) an innovative immunotherapy company seeking to advance the next...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10.077337.21714010590.20770.44770.182533681040.2818884CS
40.2038250.9852216750.08120.44770.06361779751080.24107635CS
120.155119.2307692310.130.44770.0636686322990.2245613CS
26-0.755-72.59615384621.041.080.0636344167480.22526693CS
52-4.965-94.57142857145.2512.380.0636230044900.26925908CS
156-4.965-94.57142857145.2512.380.0636230044900.26925908CS
260-4.965-94.57142857145.2512.380.0636230044900.26925908CS

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
WORXSCWorx Corporation
US$ 1,90
(93,88%)
114,82M
CRNCCerence Inc
US$ 5,0599
(79,43%)
37,81M
SPAISafe Pro Group Inc
US$ 4,55
(42,19%)
39,54M
QUBTQuantum Computing Inc
US$ 5,03
(36,68%)
100,61M
QMCOQuantum Corporation
US$ 4,08
(35,10%)
555,89k
GLXGGalaxy Payroll Group Ltd
US$ 1,88
(-51,92%)
1,49M
PYXSPyxis Oncology Inc
US$ 2,13
(-44,24%)
10,39M
KURAKura Oncology Inc
US$ 9,98
(-37,27%)
8,31M
WCTWellchange Holdings Company Limited
US$ 2,14
(-35,54%)
646,59k
BLRXBioLineRx Ltd
US$ 0,3521
(-35,42%)
6,54M
CDTConduit Pharmaceuticals Inc
US$ 0,1123
(21,67%)
505,01M
NVDANVIDIA Corporation
US$ 143,33
(-1,75%)
225,41M
AKTSAkoustis Technologies Inc
US$ 0,1028
(18,03%)
187,11M
ELABElevai Labs Inc
US$ 0,0203
(-5,14%)
179,83M
WORXSCWorx Corporation
US$ 1,90
(93,88%)
113,91M
Aucune Discussion Trouvée
Ajouter une Discussion